Since cyclothialidine was discovered as the most active DNA gyrase inhibitor in 1994, enormous efforts have been devoted to make it into a commercial medicine by a number of pharmaceutical companies and research groups worldwide. However, no serious breakthrough has been made up to now. An essential problem involved with cyclothialidine is that though it demonstrated the potent inhibition of DNA gyrase, it showed little activity against bacteria. This probably is attributable to its inability to penetrate bacterial cell walls and membranes. We applied the TSAR programme to generate a QSAR equation to the gram-negative organisms. In that equation, LogP is profoundly indicated as the key factor influencing the cyclothialidine activity against...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
doi: 10.1021/acsmedchemlett.0c00416We designed and synthesized a series of inhibitors of the bacteri...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
Since cyclothialidine was discovered as the most active DNA gyrase inhibitor in 1994, enormous effor...
Cyclothialidine, a natural product isolated from Streptomyces .filipinensis NR0484, has been proven ...
The rapidly increasing rate of antibiotic resistance is of great concern. Approximately two million ...
The impacts of multi-drug resistant bacteria have an estimated global cost of $40 billion and provid...
The impacts of multi-drug resistant bacteria have an estimated global cost of $40 billion and provid...
DNA gyrase is a well-established antibacterial target consisting of two subunits, GyrA and GyrB, in ...
Previously we have reported on a series of pyridine-3-carboxamide inhibitors of DNA gyrase and DNA t...
Type II topoisomerases like DNA gyrase initiate ATP-dependent negative supercoils in bacterial DNA. ...
We designed and synthesized a series of inhibitors of the bacterial enzymes DNA gyrase and DNA topoi...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
Antimicrobial resistance (AMR) poses an existential threat to humanity. By 2050, it is predicted tha...
We designed and synthesized a series of inhibitors of the bacterial enzymes DNA gyrase and DNA topoi...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
doi: 10.1021/acsmedchemlett.0c00416We designed and synthesized a series of inhibitors of the bacteri...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
Since cyclothialidine was discovered as the most active DNA gyrase inhibitor in 1994, enormous effor...
Cyclothialidine, a natural product isolated from Streptomyces .filipinensis NR0484, has been proven ...
The rapidly increasing rate of antibiotic resistance is of great concern. Approximately two million ...
The impacts of multi-drug resistant bacteria have an estimated global cost of $40 billion and provid...
The impacts of multi-drug resistant bacteria have an estimated global cost of $40 billion and provid...
DNA gyrase is a well-established antibacterial target consisting of two subunits, GyrA and GyrB, in ...
Previously we have reported on a series of pyridine-3-carboxamide inhibitors of DNA gyrase and DNA t...
Type II topoisomerases like DNA gyrase initiate ATP-dependent negative supercoils in bacterial DNA. ...
We designed and synthesized a series of inhibitors of the bacterial enzymes DNA gyrase and DNA topoi...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
Antimicrobial resistance (AMR) poses an existential threat to humanity. By 2050, it is predicted tha...
We designed and synthesized a series of inhibitors of the bacterial enzymes DNA gyrase and DNA topoi...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...
doi: 10.1021/acsmedchemlett.0c00416We designed and synthesized a series of inhibitors of the bacteri...
ATP competitive inhibitors of DNA gyrase and topoisomerase IV have great therapeutic potential, but ...